<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="italic;} Int J Infect DisInt J Infect DisInternational Journal of" exact="Infectious" post="Diseases1201-97121878-3511The Author(s). Published by Elsevier Ltd on behalf of"/>
 <result pre="Published by Elsevier Ltd on behalf of International Society for" exact="Infectious" post="Diseases. pmcid: 7326458S1201-9712(20)30528-2 doi: 10.1016/j.ijid.2020.06.093 : Case Report Case"/>
 <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
 <result pre="and treated with remdesivir for compassionate use. â€¢For two patients," exact="viral" post="loads in nasopharyngeal samples decreased, despite active replication in"/>
 <result pre="loads in nasopharyngeal samples decreased, despite active replication in the" exact="lower" post="respiratory tract area. â€¢The treatment had to be interrupted"/>
 <result pre="in nasopharyngeal samples decreased, despite active replication in the lower" exact="respiratory" post="tract area. â€¢The treatment had to be interrupted in"/>
 <result pre="four of the five patients, because of ALT elevation and/or" exact="renal failure." post="Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has"/>
 <result pre="five patients, because of ALT elevation and/or renal failure. Abstract" exact="Severe" post="acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been identified"/>
 <result pre="patients, because of ALT elevation and/or renal failure. Abstract Severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) has been identified as"/>
 <result pre="because of ALT elevation and/or renal failure. Abstract Severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) has been identified as the"/>
 <result pre="of ALT elevation and/or renal failure. Abstract Severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) has been identified as the virus"/>
 <result pre="has been identified as the virus responsible for the coronavirus" exact="disease" post="2019 (COVID-19) outbreak worldwide. Data on treatment are scare"/>
 <result pre="unit of Bichat-Claude Bernard University Hospital, Paris, France, for severe" exact="pneumonia" post="related to SARS-CoV-2 and treated with remdesivir. Quantitative reverse"/>
 <result pre="was used to monitor SARS-CoV-2 in blood plasma and the" exact="lower" post="and upper respiratory tract. Among the five patients treated,"/>
 <result pre="to monitor SARS-CoV-2 in blood plasma and the lower and" exact="upper" post="respiratory tract. Among the five patients treated, two needed"/>
 <result pre="monitor SARS-CoV-2 in blood plasma and the lower and upper" exact="respiratory" post="tract. Among the five patients treated, two needed mechanical"/>
 <result pre="one needed high-flow cannula oxygen. A significant decrease in SARS-CoV-2" exact="viral" post="load in the upper respiratory tract was observed in"/>
 <result pre="oxygen. A significant decrease in SARS-CoV-2 viral load in the" exact="upper" post="respiratory tract was observed in most cases, but two"/>
 <result pre="A significant decrease in SARS-CoV-2 viral load in the upper" exact="respiratory" post="tract was observed in most cases, but two patients"/>
 <result pre="but two patients died with active SARS-CoV-2 replication in the" exact="lower" post="respiratory tract. Plasma samples were positive for SARS-CoV-2 in"/>
 <result pre="two patients died with active SARS-CoV-2 replication in the lower" exact="respiratory" post="tract. Plasma samples were positive for SARS-CoV-2 in only"/>
 <result pre="elevations (3 to 5 normal range) and two because of" exact="renal failure" post="requiring renal replacement. This case series of five COVID-19"/>
 <result pre="of five COVID-19 patients requiring intensive care unit treatment for" exact="respiratory" post="distress and treated with remdesivir, highlights the complexity of"/>
 <result pre="of remdesivir use in such critically ill patients. Keywords SARS-CoV-2" exact="viral" post="load Remdesivir Antiviral therapy Viral pneumonia Case reports Introduction"/>
 <result pre="critically ill patients. Keywords SARS-CoV-2 viral load Remdesivir Antiviral therapy" exact="Viral" post="pneumonia Case reports Introduction In December 2019, severe acute"/>
 <result pre="ill patients. Keywords SARS-CoV-2 viral load Remdesivir Antiviral therapy Viral" exact="pneumonia" post="Case reports Introduction In December 2019, severe acute respiratory"/>
 <result pre="therapy Viral pneumonia Case reports Introduction In December 2019, severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified as responsible"/>
 <result pre="Viral pneumonia Case reports Introduction In December 2019, severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) was identified as responsible for"/>
 <result pre="pneumonia Case reports Introduction In December 2019, severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) was identified as responsible for the"/>
 <result pre="coronavirus 2 (SARS-CoV-2) was identified as responsible for the coronavirus" exact="disease" post="2019 (COVID-19) outbreak that started in China (Zhu et"/>
 <result pre="(Zhu et al., 2020). Treatment options investigated during previous severe" exact="acute" post="respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS)"/>
 <result pre="et al., 2020). Treatment options investigated during previous severe acute" exact="respiratory" post="syndrome (SARS) and Middle East respiratory syndrome (MERS) epidemics,"/>
 <result pre="al., 2020). Treatment options investigated during previous severe acute respiratory" exact="syndrome" post="(SARS) and Middle East respiratory syndrome (MERS) epidemics, both"/>
 <result pre="during previous severe acute respiratory syndrome (SARS) and Middle East" exact="respiratory" post="syndrome (MERS) epidemics, both caused by other viruses of"/>
 <result pre="previous severe acute respiratory syndrome (SARS) and Middle East respiratory" exact="syndrome" post="(MERS) epidemics, both caused by other viruses of the"/>
 <result pre="described previously (Lescure et al., 2020). Here we describe the" exact="complete" post="follow-up, drug tolerance, and virological monitoring of these five"/>
 <result pre="individual patients, due to the retrospective chart review design and" exact="absence of" post="identifying images or personal/clinical details that could compromise anonymity."/>
 <result pre="sample without virological transport medium using the usual procedures for" exact="bacterial" post="growth. Bronchoalveolar lavage fluid was also tested with an"/>
 <result pre="fluid was also tested with an multiplex PCR assay (FilmArray" exact="Pneumonia" post="assay; BioFire, BioMÃ©rieux) for virus and bacteria detection, and"/>
 <result pre="after arriving in Paris. He was immediately hospitalized with mild" exact="lymphopenia" post="(1.00 Ã— 109/l) and thrombocytopenia (1.46 Ã— 109/l); there"/>
 <result pre="was immediately hospitalized with mild lymphopenia (1.00 Ã— 109/l) and" exact="thrombocytopenia" post="(1.46 Ã— 109/l); there were no abnormalities on chest"/>
 <result pre="and thrombocytopenia (1.46 Ã— 109/l); there were no abnormalities on" exact="chest" post="X-ray. RT-qPCR on nasopharyngeal samples was positive, with a"/>
 <result pre="X-ray. RT-qPCR on nasopharyngeal samples was positive, with a SARS-CoV-2" exact="viral" post="load (VL) of 10.5 log10 copies/ml. On day 10"/>
 <result pre="(PO2 = 58 mmHg; low-flow nasal cannula 4 l/min) and" exact="bilateral" post="ground-glass and alveolar opacities on chest computed tomography (CT)"/>
 <result pre="cannula 4 l/min) and bilateral ground-glass and alveolar opacities on" exact="chest" post="computed tomography (CT) scan with no increase in VL."/>
 <result pre="patient was discharged on February 12. Figure 1 Clinical and" exact="viral" post="evolution of the case patients. For each patient, the"/>
 <result pre="dashed blue line, and remdesivir infusion by the red line." exact="Viral" post="load is shown with black diamonds, nasopharyngeal swabs with"/>
 <result pre="shown with black diamonds, nasopharyngeal swabs with a black line," exact="lower" post="respiratory tract samples (when available) with green squares, and"/>
 <result pre="with black diamonds, nasopharyngeal swabs with a black line, lower" exact="respiratory" post="tract samples (when available) with green squares, and plasma"/>
 <result pre="with green squares, and plasma samples with red circles. The" exact="viral" post="load was estimated by cycle threshold (Ct) values; the"/>
 <result pre="viral load was estimated by cycle threshold (Ct) values; the" exact="lower" post="the Ct value, the higher is the viral load."/>
 <result pre="values; the lower the Ct value, the higher is the" exact="viral" post="load. A sample is negative above a Ct value"/>
 <result pre="originating from Hubei Province, with a past medical history of" exact="thyroid cancer," post="presented on January 25 with fever and diarrhoea of"/>
 <result pre="January 25 with fever and diarrhoea of 4-day duration. A" exact="chest" post="X-ray showed bilateral alveolar opacities, but he did not"/>
 <result pre="fever and diarrhoea of 4-day duration. A chest X-ray showed" exact="bilateral" post="alveolar opacities, but he did not fulfil the COVID-19"/>
 <result pre="COVID-19 was eventually made 3 days later. On January 26," exact="acute" post="respiratory failure with multiple organ failure triggered his admission"/>
 <result pre="was eventually made 3 days later. On January 26, acute" exact="respiratory" post="failure with multiple organ failure triggered his admission to"/>
 <result pre="therapy was started and adapted for co-infection with a susceptible" exact="Acinetobacter" post="baumannii (diagnosed by multiplex PCR and confirmed by tracheal"/>
 <result pre="of infusion. A CT scan performed on January 31 showed" exact="bilateral" post="alveolar condensations, ground-glass opacities, and pulmonary cysts. On February"/>
 <result pre="on January 31 showed bilateral alveolar condensations, ground-glass opacities, and" exact="pulmonary" post="cysts. On February 5, because of the disease severity"/>
 <result pre="opacities, and pulmonary cysts. On February 5, because of the" exact="disease" post="severity and the persistence of viral detection, remdesivir was"/>
 <result pre="5, because of the disease severity and the persistence of" exact="viral" post="detection, remdesivir was re-initiated. Multiple organ failure persisted without"/>
 <result pre="severity and the persistence of viral detection, remdesivir was re-initiated." exact="Multiple" post="organ failure persisted without any other co-infection identified. He"/>
 <result pre="was obese (body mass index = 33 kg/m2) and had" exact="obstructive sleep apnoea" post="syndrome, was diagnosed with severe COVID-19 and admitted to"/>
 <result pre="had a cough and fever since February 21. He presented" exact="acute" post="respiratory failure (PaO2 = 74 mmHg; high-flow nasal cannula"/>
 <result pre="a cough and fever since February 21. He presented acute" exact="respiratory" post="failure (PaO2 = 74 mmHg; high-flow nasal cannula 40"/>
 <result pre="mmHg; high-flow nasal cannula 40 l/min, 40%) and basal interstitial" exact="syndrome" post="on chest X-ray. Remdesivir was started on February 27."/>
 <result pre="nasal cannula 40 l/min, 40%) and basal interstitial syndrome on" exact="chest" post="X-ray. Remdesivir was started on February 27. Viral RNA"/>
 <result pre="syndrome on chest X-ray. Remdesivir was started on February 27." exact="Viral" post="RNA levels increased slightly from a Ct value of"/>
 <result pre="until undetectability. On March 1, he was referred to the" exact="infectious diseases" post="ward, and he was weaned off oxygen on day"/>
 <result pre="Case 4 A 76-year-old French male, with a history of" exact="chronic" post="kidney injury (creatinine 115 Î¼mol/l, normal range 50â€&quot;70 Î¼mol/l),"/>
 <result pre="4 A 76-year-old French male, with a history of chronic" exact="kidney injury" post="(creatinine 115 Î¼mol/l, normal range 50â€&quot;70 Î¼mol/l), was admitted"/>
 <result pre="presented an SpO2 of 92% on room air and showed" exact="posterior" post="pulmonary ground-glass opacities on chest CT scan. On day"/>
 <result pre="an SpO2 of 92% on room air and showed posterior" exact="pulmonary" post="ground-glass opacities on chest CT scan. On day 11"/>
 <result pre="on room air and showed posterior pulmonary ground-glass opacities on" exact="chest" post="CT scan. On day 11 of illness, he was"/>
 <result pre="5 A 70-year-old male with a past medical history of" exact="chronic" post="obstructive pulmonary disease was diagnosed with COVID-19 on March"/>
 <result pre="70-year-old male with a past medical history of chronic obstructive" exact="pulmonary" post="disease was diagnosed with COVID-19 on March 1. He"/>
 <result pre="male with a past medical history of chronic obstructive pulmonary" exact="disease" post="was diagnosed with COVID-19 on March 1. He had"/>
 <result pre="He was admitted to the ICU on March 2 with" exact="acute" post="respiratory distress syndrome. Remdesivir was started on March 4"/>
 <result pre="was admitted to the ICU on March 2 with acute" exact="respiratory" post="distress syndrome. Remdesivir was started on March 4 (day"/>
 <result pre="11 of illness) and discontinued on March 6 because of" exact="acute" post="kidney injury (creatinine level up to 396 Î¼mol/l) needing"/>
 <result pre="of illness) and discontinued on March 6 because of acute" exact="kidney injury" post="(creatinine level up to 396 Î¼mol/l) needing renal replacement"/>
 <result pre="March 10. Cefotaxime was initiated because of a Haemophilus influenzae" exact="respiratory" post="co-infection. Nevertheless, he developed multiple organ failure and refractory"/>
 <result pre="respiratory co-infection. Nevertheless, he developed multiple organ failure and refractory" exact="acute" post="respiratory distress syndrome despite prone positioning and adapted mechanical"/>
 <result pre="co-infection. Nevertheless, he developed multiple organ failure and refractory acute" exact="respiratory" post="distress syndrome despite prone positioning and adapted mechanical ventilation."/>
 <result pre="he developed multiple organ failure and refractory acute respiratory distress" exact="syndrome" post="despite prone positioning and adapted mechanical ventilation. Dexamethasone and"/>
 <result pre="case series of five COVID-19 patients requiring ICU treatment for" exact="respiratory" post="distress and treated with remdesivir, three (patients 1, 3,"/>
 <result pre="3, and 4) had a favourable outcome despite the initial" exact="respiratory" post="severity. They were weaned off oxygen between day 14"/>
 <result pre="early interruption, without any additional decrease in VL in the" exact="upper" post="or lower respiratory tract. For patient 5, viral replication"/>
 <result pre="without any additional decrease in VL in the upper or" exact="lower" post="respiratory tract. For patient 5, viral replication was still"/>
 <result pre="any additional decrease in VL in the upper or lower" exact="respiratory" post="tract. For patient 5, viral replication was still ongoing"/>
 <result pre="in the upper or lower respiratory tract. For patient 5," exact="viral" post="replication was still ongoing in the lower respiratory tract"/>
 <result pre="For patient 5, viral replication was still ongoing in the" exact="lower" post="respiratory tract despite a concomitant undetectable VL in the"/>
 <result pre="patient 5, viral replication was still ongoing in the lower" exact="respiratory" post="tract despite a concomitant undetectable VL in the nasopharyngeal"/>
 <result pre="undetectable VL in the nasopharyngeal area, highlighting the discrepancies between" exact="viral" post="replication in the upper and lower respiratory tract among"/>
 <result pre="nasopharyngeal area, highlighting the discrepancies between viral replication in the" exact="upper" post="and lower respiratory tract among the most severe patients."/>
 <result pre="highlighting the discrepancies between viral replication in the upper and" exact="lower" post="respiratory tract among the most severe patients. Plasma samples"/>
 <result pre="the discrepancies between viral replication in the upper and lower" exact="respiratory" post="tract among the most severe patients. Plasma samples were"/>
 <result pre="experienced major side effects while on remdesivir treatment: two suffered" exact="acute" post="renal injury and two had a maculopapular rash with"/>
 <result pre="acute renal injury and two had a maculopapular rash with" exact="cytolytic hepatitis." post="Both kidney failure events could have been related either"/>
 <result pre="and two had a maculopapular rash with cytolytic hepatitis. Both" exact="kidney failure" post="events could have been related either to remdesivir or"/>
 <result pre="a median follow-up of 18 days after remdesivir initiation, a" exact="total" post="of 25 (47%) were discharged; seven (13%) died and"/>
 <result pre="the manuscript and took care of the patients in the" exact="infectious" post="and tropical diseases department. LD, DLP, and CR took"/>
 <result pre="DLP, and CR took care of the patients in the" exact="infectious" post="and tropical diseases department. BV participated to the virological"/>
 <result pre="PHW took care of the patients in the medical and" exact="infectious" post="intensive care unit. LK assisted in obtaining and dispensing"/>
 <result pre="individual patients, due to the retrospective chart review design and" exact="absence of" post="identifying images or personal/clinical details that could compromise anonymity."/>
 <result pre="no competing interests. References References ArabiY.M.AsiriA.Y.AssiriA.M.Aziz JokhdarH.A.AlothmanA.BalkhyH.H.Treatment of Middle East" exact="respiratory" post="syndrome with a combination of lopinavir/ritonavir and interferon-Î²1b (MIRACLE"/>
 <result pre="competing interests. References References ArabiY.M.AsiriA.Y.AssiriA.M.Aziz JokhdarH.A.AlothmanA.BalkhyH.H.Treatment of Middle East respiratory" exact="syndrome" post="with a combination of lopinavir/ritonavir and interferon-Î²1b (MIRACLE trial):"/>
 <result pre="United StatesN Engl J Med38210202092993632004427 KujawskiS.A.WongK.K.CollinsJ.P.EpsteinL.KillerbyM.E.MidgleyC.M.First 12 patients with coronavirus" exact="disease" post="2019 (COVID-19) in the United StatesmedRxivJanuary20202020.03.09.20032896 LescureF.-X.BouadmaL.NguyenD.PariseyM.WickyP.-H.BehillilS.Clinical and virological"/>
 <result pre="case seriesLancet Infect DisMarch2020 MartinezM.A.Compounds with therapeutic potential against novel" exact="respiratory" post="2019 coronavirusAntimicrob Agents ChemotherMarch2020 MulanguS.DoddL.E.DaveyR.T.Tshiani MbayaO.ProschanM.MukadiD.A randomized, controlled trial"/>
 <result pre="Agents ChemotherMarch2020 MulanguS.DoddL.E.DaveyR.T.Tshiani MbayaO.ProschanM.MukadiD.A randomized, controlled trial of ebola virus" exact="disease" post="therapeuticsN Engl J Med3812420192293230331774950 SavarinoA.Di TraniL.DonatelliI.CaudaR.CassoneA.New insights into the"/>
 <result pre="[Cited 12 May 2020] ZhuN.ZhangD.WangW.LiX.YangB.SongJ.A novel coronavirus from patients with" exact="pneumonia" post="in China, 2019N Engl J Med3828202072773331978945"/>
</results>
